Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBAN
2024-517621-54-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in bladder cancer (2 arms), sponsored by Unicancer. Primary endpoint: Event-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-517621-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517621-54-00.